|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
<b>Conclusion:</b> The effects of CAPON-L overexpression on glioma cell proliferation are dependent on the AKT/mTOR/P53 activity.
|
31171914 |
2019 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ACT001, a novel PAI-1 inhibitor, exerts synergistic effects in combination with cisplatin by inhibiting PI3K/AKT pathway in glioma.
|
31591377 |
2019 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Although signaling from phosphatidylinositol 3-kinase (PI3K) and AKT to mechanistic target of rapamycin (mTOR) is prominently dysregulated in high-grade glial brain tumors, blockade of PI3K or AKT minimally affects downstream mTOR activity in glioma.
|
28292440 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF-β/PI3K/AKT/mTOR signalling pathway.
|
31776938 |
2020 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared with control group, an increased expression of miR-21, PI3K, AKT, p-AKT, P53, and p-GSK3, and a decreased expression of SPRY1, PTEN, Caspase-3, and Caspase-9 were observed in the glioma group, and no significant differences were found in the expression of GSK3.
|
29316313 |
2018 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Depletion of Akt2 expression by siRNA also abrogates TWEAK-stimulated glioma cell survival, whereas no effect on glioma cell survival was observed after siRNA-mediated depletion of Akt1 expression.
|
19861406 |
2009 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Evodiamine activates cellular apoptosis through suppressing PI3K/AKT and activating MAPK in glioma.
|
29535541 |
2018 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, the association between therapeutic efficacy and putative proapoptotic activity of low-dose BVZ either alone or in combination with a specific inhibitor of AKT called perifosine (PRF), in a glioma model was investigated.
|
28616662 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our results support the concept that β-catenin/Tcf-4 directly regulates AKT1 in glioma, and these two proteins may cooperate with each other in exerting their oncogenic effects in glioma.
|
21720709 |
2011 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study suggests that SPOCK1 promotes proliferation, migration and invasion in glioma cells by activating PI3K/AKT and Wnt/β-catenin pathways, which provides a potential theoretical basis for clinical treatment of glioma.
|
27108836 |
2016 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, KEGG PathwayFinder by gene correlation analysis was performed on the R2: Genomics Analysis and Visualization Platform, which revealed a high association between Ngb and the phosphatidylinositol 3‑kinase (PI3K)/AKT pathway using glioma data (GSE4290) from the Gene Expression Omnibus database.
|
29207186 |
2018 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we confirmed that lncRNA SNHG16 was highly expressed in glioma and may exert oncogenic function as a competing endogenous RNA (ceRNA) to regulate EGFR by sponging of miR-373-3p through activating PI3K/AKT pathway, which providing a new insight of the regulatory network of lncRNA SNHG16 in the development of glioma.
|
31226483 |
2020 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Its efficacy as a single agent or in combination with TMZ was assessed <i>in vitro</i> and <i>in vivo</i> using zebrafish and patient-derived GSC xenograft mouse glioma models.<b>Results:</b> Onalespib-mediated HSP90 inhibition depleted several survival-promoting client proteins such as EGFR, EGFRvIII, and AKT, disrupted their downstream signaling, and decreased the proliferation, migration, angiogenesis, and survival of glioma cell lines and GSCs.
|
28679777 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MicroRNA-1231 exerts a tumor suppressor role through regulating the EGFR/PI3K/AKT axis in glioma.
|
29774498 |
2018 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-199a-3p in glioma cell lines has effects similar to the tumor suppressor gene on cellular proliferation via the AKT/mTOR signaling pathway.
|
25854175 |
2015 |
|
Glioma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Moreover, NGB participates in regulating the phosphorylation of AKT in glioma cells, which may contribute to the glioma progression where accumulating oxidative pressure presents.
|
28410531 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our focus on these proteins was due to the fact that they are involved in the PI3K/AKT/mTOR and RAS/RAF/MAPK pathways, known for their contribution to the development and progression of gliomas.
|
20533335 |
2010 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results indicated that BCL6 may be a tumor oncogene involved in the progression of glioma via affecting AKT and MAPK signaling pathways.
|
30420967 |
2018 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of miR-770 indicates a favorable prognosis and suppresses tumorigenesis by modulating PI3K-AKT pathway in glioma.
|
31002138 |
2019 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PERK silence inhibits glioma cell growth under low glucose stress by blockage of p-AKT and subsequent HK2's mitochondria translocation.
|
25761777 |
2015 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PI3K-AKT-mTOR signaling is a valuable treatment target for human glioma.
|
29228741 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preclinical data in a pediatric glioma model demonstrated that the combination of perifosine (AKT inhibitor) and temsirolimus (mTOR inhibitor) is more potent at inhibiting the axis than either agent alone.
|
28035748 |
2017 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
PTEN down regulates AP-1 and targets c-fos in human glioma cells via PI3-kinase/Akt pathway.
|
17235455 |
2007 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Reasons for treatment failure include poor penetration of agents into the brain and observations that blockade of PI3K or AKT minimally affects downstream mTOR activity in glioma.
|
28696243 |
2018 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies have showed that regulation of the EGFR/PTEN/AKT pathway by miRNAs plays a major role in glioma progression, indicating a novel way to investigate the tumorigenesis, diagnosis, and therapy of gliomas.
|
21842313 |
2012 |